StemRIM Inc. Logo

StemRIM Inc.

Developing regenerative medicines that use the body's own stem cells to treat intractable diseases.

4599 | T

Overview

Corporate Details

ISIN(s):
JP3399690001
LEI:
Country:
Japan
Address:
茨木市彩都あさぎ7丁目7番15号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

StemRIM Inc. is a biotechnology company engaged in the research and development of a next-generation class of regenerative medicine called "Regeneration-Inducing Medicine™". Originating as a venture from Osaka University, the company focuses on developing drugs with a novel mechanism of action. This approach aims to maximize the body's innate ability to repair itself by recruiting a patient's own in-vivo stem cells to damaged tissues, thereby inducing functional regeneration without conventional cell-therapy. The company's drug development pipelines target intractable diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 06:38
Registration Form
有価証券届出書(参照方式)
Japanese 49.2 KB
2025-10-21 08:10
Registration Form
確認書
Japanese 8.1 KB
2025-10-21 08:10
Annual Report
有価証券報告書-第20期(2024/08/01-2025/07/31)
Japanese 2.7 MB
2025-09-12 05:32
Share Issue/Capital Change
訂正臨時報告書
Japanese 30.7 KB
2025-03-13 04:31
Report Publication Announcement
確認書
Japanese 8.0 KB
2025-03-13 04:30
Interim Report
半期報告書-第20期(2024/08/01-2025/07/31)
Japanese 228.6 KB
2024-11-25 08:13
Registration Form
有価証券届出書(参照方式)
Japanese 49.5 KB
2024-11-18 01:31
Share Issue/Capital Change
訂正臨時報告書
Japanese 32.6 KB
2024-11-13 08:10
Regulatory News Service
臨時報告書
Japanese 36.2 KB
2024-10-31 05:28
Post-Annual General Meeting Information
臨時報告書
Japanese 22.4 KB
2024-10-31 03:35
Governance Information
内部統制報告書-第19期(2023/08/01-2024/07/31)
Japanese 21.0 KB
2024-10-31 03:35
Registration Form
確認書
Japanese 8.1 KB
2024-10-31 03:32
Annual Report
有価証券報告書-第19期(2023/08/01-2024/07/31)
Japanese 2.7 MB
2024-07-26 08:53
Regulatory News Service
臨時報告書
Japanese 35.7 KB
2024-07-26 08:53
Regulatory News Service
臨時報告書
Japanese 35.8 KB

Automate Your Workflow. Get a real-time feed of all StemRIM Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for StemRIM Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for StemRIM Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.